title: Serum-soluble interleukin-2 receptor levels before and after surgical treatment for Graves' disease.
abstract: Serum-soluble interleukin-2 receptor (ssIL-2R) is released from its specific affinity membrane receptor on activated T lymphocytes and is detected as a form of the alpha-chain of IL-2R in the peripheral blood. We measured the ssIL-2R levels by enzyme-linked immunosorbent assay in 29 healthy subjects and 39 patients with Graves' disease who were given antithyroid drugs to prepare them for surgical treatment. The preoperative ssIL-2R levels in Graves' patients were significantly higher than those in the healthy controls (681 +/- 387 vs 369 +/- 149 U/ml); in particular, the preoperative levels in hyperthyroid patients were significantly higher than those in euthyroid patients. On the 5th day after thyroid resection, their ssIL-2R levels (560 +/- 296 U/ml) were significantly lower than the preoperative levels. There were no correlations between the preoperative ssIL-2R levels and the immunological parameters such as thyroglobulin antibody, microsomal antibody, and thyroid-stimulating hormone receptor antibody. Thus, we conclude that ssIL-2R levels can be decreased by surgical resection of goiter in Graves' patients whose hyperthyroid status does not respond to the administration of antithyroid drugs, and this may be a useful indicator of immunological status after surgical treatment of Graves' disease.
authors.affiliation: Second Department of Surgery, Saitama Medical School, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Murakami
authors.forename: A
authors.initials: A
authors.lastname: Kobayashi
authors.forename: K
authors.initials: K
authors.lastname: Kuma
authors.forename: H
authors.initials: H
authors.lastname: Murai
authors.forename: Y
authors.initials: Y
authors.lastname: Okamura
authors.forename: A
authors.initials: A
authors.lastname: Satomi
authors.forename: K
authors.initials: K
authors.lastname: Ishida
mesh_terms: D000328:Adult; D013956:Antithyroid Agents / Q000627:therapeutic use; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006111:Graves Disease / Q000097:blood* / Q000188:drug therapy / Q000276:immunology / Q000601:surgery*; D006801:Humans; D018828:Immunoglobulins, Thyroid-Stimulating / Q000097:blood; D008297:Male; D015375:Receptors, Interleukin-2 / Q000378:metabolism*; D013954:Thyroglobulin / Q000276:immunology
chemical_list: D013956:Antithyroid Agents; D018828:Immunoglobulins, Thyroid-Stimulating; D015375:Receptors, Interleukin-2; D013954:Thyroglobulin